In fact, the prevalence of BCR::ABL1 in the All of Us (0.019%) closely matches the prevalence of CML in the United States (0.02%)30, indicating that BCR::ABL1 does not also drive asymptomatic CH. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.